Real-life data of ten years with omalizumab treatment - Milan 2023

Real-life studies in asthma: all the way to clinical remission

Chair(s): Celeste Michala Porsbjerg, Andrea Portacci

Session type: Poster session

Real-life data of ten years with omalizumab treatment

Gokcen Omeroglu Simsek

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma

Ipek Kivilcim Oguzulgen

Poster

Abstract

Patients' knowledge, perspectives and attitudes towards treatment goals and clinical remission in severe asthma

Shiyuan Zhang

Poster

Abstract

Asthma medication use in New Zealand following publication of national asthma guidelines

Lee Hatter

Poster

Abstract

Treatment Patterns of Patients Who Initiate Biologics for Severe Asthma Across USA, Japan, & Europe

Joshua Harvey

Poster

Abstract

Clinical remission following biologic initiation in severe asthma: results of the International Severe Asthma Registry (ISAR)

Trung Tran

Poster

Abstract

Real-life oral corticosteroid sparring effects of biologic treatment on eosinophilic asthma, five years of follow-up

Soran Peshbahar

Poster

Abstract

Long-term weight changes after starting anti-interleukin-5/5Ra biologics in severe asthma

Lianne Ten Have

Poster

Abstract

Characteristics associated with clinical remission in patients with severe asthma who initiate biologics

Luis Perez De Llano

Poster

Abstract

Efficacy of benralizumab and mepolizumab in treating severe eosinophilic asthma: A one-year study on clinical remission and response

Anna Nunez

Poster

Abstract

Benralizumab effectiveness in severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective study.

Raffaele Campisi

Poster

Abstract

Real-life data of ten years with omalizumab treatment

Gokcen Omeroglu Simsek

Poster

Abstract

Multi-country self-controlled study of exacerbation rates in severe asthma patients treated with mepolizumab: NEST interim analysis

Sevim Bavbek

Poster

Abstract

Clinical remission (CR) in a real-world study to evaluate mepolizumab effectiveness in treating severe eosinophilic asthma (SEA) in Taiwan (REMIT)

Aldo Navarro

Poster

Abstract

Multicentric real life experience of mepolizumab in bronchiectasis concomitant to severe asthma.

Juan Luis Garcia Rivero

Poster

Abstract

Real world biologic treatment response in severe asthma: an analysis of the International Severe Asthma Registry (ISAR)

Trung Tran

Poster

Abstract

Attitudes and experiences of patients and healthcare practitioners towards asthma medication prescription and adherence in the UK

Xiubin Zhang

Poster

Abstract

Early response to benralizumab in severe, eosinophilic asthma: a real-world study in Switzerland

Claudio Schuoler

Poster

Abstract

Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

David Price

Poster

Abstract

Real-world experience of mepolizumab in severe eosinophilic asthma five-year outcomes

Amy Nuttall

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}